Bayer Shares Walk a Tightrope as Kidney Drug Study Offers a Glimmer of Pipeline Promise

Bayer shares rose 1.58% but remain down 5.46% YTD. Strong Finerenon kidney data fails to catalyze stock as Roundup litigation and lack of near-term catalysts persist.

Friday’s 1.58% advance to €35.95 gave Bayer a friendly end to the week, but the underlying picture remains far from settled. The stock has slid 6.67% over the past 30 days and sits 5.46% lower since the start of the year, even as the 12-month return still shows a hefty 36.77% gain. That dissonance reflects an equity caught between a promising pharma pipeline and an unresolved legal overhang.

The latest clinical news could eventually tip the scales. On 5 June, Bayer announced that its phase III FIND-CKD trial met its primary endpoint: Finerenon, marketed as Kerendia, slowed kidney function decline in adults with non-diabetic chronic kidney disease by a statistically significant 0.7 ml/min/1.73 m² per year in eGFR slope versus placebo. A composite cardiovascular-renal secondary endpoint fell 23%. The data were unveiled simultaneously at the ERA Congress and in the New England Journal of Medicine, and Bayer plans to submit them to regulators for a label expansion — though no timeline for approval was given.

An even broader picture emerged from the INFINITY pooled analysis, which combined three phase III trials — FIDELIO-DKD, FIGARO-DKD and FIND-CKD — covering roughly 14,500 patients. In that meta-analysis, Finerenon cut the primary composite renal endpoint by 24% and reduced hospitalisation for heart failure or cardiovascular death by 20%. The results appeared in The Lancet, giving regulators an unusually robust dataset to consider. Kerendia is one of the few growth pillars in Bayer’s pharma division, which posted first-quarter 2026 revenue of €4.249 billion — virtually flat year-on-year as gains from Kerendia and Nubeqa offset patent losses elsewhere.

Yet the stock has barely reacted. The close at €35.95 is just 0.41% above the 200-day moving average of €35.80 — a hair’s breadth that separates stability from renewed doubts. Below that, the 50-day average of €38.39 stands 6.36% higher, confirming the short-term trend remains under pressure. The RSI of 42.6 sits neutral, while 30-day volatility of 36.97% serves as a reminder that Bayer is not a comfort trade. The share is 28% off its 52-week high of €49.93 set in February 2026 but 43% above the 52-week low of €25.09 from August 2025.

Investors are also digesting strategic clarity — or the lack of it. Reuters reported in early June that Bayer has no plans to spin off Monsanto, despite the ongoing burden of Roundup litigation. A company representative stressed that management is focused on operational improvements and managing legal risks, rather than pursuing a break-up. That stance turns the stock into a bet on a slow, organic turnaround rather than a catalyst-driven event.

The coming days offer no company-specific trigger: the next scheduled milestones are the half-year report in August and a crop science event in September. Instead, Bayer shares will be pulled into the slipstream of macro events. The European Central Bank meets on 11 June, and final inflation data for Germany and the US are due. For a firm whose valuation is sensitive to interest rates — which affect both discount rates and financing costs — and whose agricultural division feels every shift in crop prices and currencies, the macro backdrop matters more than usual.

Analysts, however, see substantial upside. The consensus price target of €48.82 carries a strong buy recommendation from nine of the eleven analysts covering the stock. Their call hinges not on a single legal settlement or a quick spin-off, but on the belief that Bayer’s pipeline and operational recovery can eventually outweigh the legacy liabilities.

For now, the equity is marking time. The Finerenon data add a credible future catalyst, but they do nothing to ease the immediate pressures from litigation, macro headwinds and a lack of structural simplification. Every new week becomes a test of endurance: can the market keep granting Bayer the patience it demands?